Diagnosi, protesi, vaccini, genomica: la medicina che guadagna anni di vita.
La medicina che guadagna anni di vita: screening assistiti dall’IA che esaminano milioni di pazienti, vaccini di nuova generazione, una genomica che passa dal sequenziamento alla terapia, protesi e impianti che restituiscono capacità perdute. La rubrica segue le sperimentazioni cliniche concluse, le autorizzazioni all’immissione in commercio, le adozioni ospedaliere — il momento in cui una tecnologia smette di essere una pubblicazione per diventare una cura.
I numeri comandano: coorti, tassi di rilevamento, mortalità evitata, costi. Copriamo volentieri i sistemi sanitari che adottano su larga scala — l’India, il Brasile, il Sud-est asiatico — perché le tecnologie frugali si mettono spesso alla prova lì prima di arrivare altrove. Ogni articolo si appoggia alla sperimentazione, all’autorizzazione o allo studio che lo fonda, e li cita.
A registry found untreated patients and offered a specialist telephone consultation through Denmark’s Digital Post system.
Medical rehabilitation is the clearest near-term business path for non-invasive brain-computer interfaces.
The phase 2 SHIELD-MI trial tested four intravenous doses around emergency angioplasty.
The PRAGUE-26 trial randomized 558 patients at 11 Czech sites to catheter therapy or anticoagulation alone.
The NEXAF trial tested eight supervised sessions followed by home exercise and digital monitoring.
The LAACS-2 trial found no significant overall reduction in stroke or transient ischemic attack.
The ongoing study covered 3,112 patients across 23 Swedish centers after type 1 heart attacks.
The randomized trial covered 1,507 adults with reduced-ejection-fraction heart failure across 22 Indian centers.
Researchers tested a 3–6 km/h treadmill pace, close to walking, at about 35% of peak oxygen uptake.
The AIR-STEMI trial enrolled 1,823 patients at 21 centers in Italy and Pakistan.
Rice University and ETH Zurich grew human sensory neurons with Schwann cells, which form the myelin coating around nerve fibers.
UChicago researchers mapped how tumor cells organize into spatial groups across 262 solid tumors.
The pathway was found in blood samples from children with hemolytic uremic syndrome.
The seven-year study involved 33,995 adults in 326 rural Chinese villages.
The drug occupied the same primary binding pocket as morphine, but used weaker hydrophobic interactions.
In 1,199 frail adults across 11 European countries, the intervention cut risk by 22% overall.
Hypoxanthine prompts gut cells to release serotonin, while butyrate makes their response stronger.
The oral drug was tested for 24 weeks in 375 patients across 57 centers in 10 countries.